Clinical Trial Update: Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency [Phase 3]

View source ↗

Summary

An ongoing Phase 3 clinical trial is evaluating Everolimus in castration-resistant prostate cancer patients who have deficiencies in the PI3K-AKT-mTOR signaling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Prostate Cancer | Phase 3 | Status: UNKNOWN